NCT02602184View on ClinicalTrials.gov

Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds

PHASE2UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Wounds and Injuries
Interventions
DRUG

AR/101

DRUG

Placebo

Trial Locations (1)

60611

RECRUITING

Northwestern University Feinberg School of Medicine, Chicago

Sponsors

Collaborators (1)

Cato Research
All Listed Sponsors
collaborator

Cato Research

INDUSTRY

lead

Arava Bio Tech Ltd.

INDUSTRY